论文部分内容阅读
目的观察粒细胞集落刺激因子格拉诺赛特治疗肺癌患者化疗所致Ⅳ度中性粒细胞减少症的疗效及安全性。方法43例肺癌患者接受含铂方案化疗后出现Ⅳ度中性粒细胞减少症,应用格拉诺赛特250μg,每天一次,皮下注射,直至患者中性粒细胞脱离Ⅳ度或恢复正常。结果格拉诺赛特中位使用时间为1.5 d。43例患者均脱离Ⅳ度中性粒细胞减少,其中13例恢复至正常。主要不良反应为发热、肌肉酸痛等表现,均较轻微且为可逆性。结论格拉诺赛特治疗肺癌患者化疗所致中性粒细胞作用明显,耐受性好。
Objective To observe the efficacy and safety of granograstid colony stimulating factor Granolast in the treatment of Ⅳ neutropenia induced by chemotherapy in patients with lung cancer. Methods A total of 43 patients with lung cancer underwent IV neutropenia after chemotherapy with platinum regimen. The patients were treated with granisexter 250 μg once a day for subcutaneous injection until the neutrophil detachment degree Ⅳ or returned to normal. The result was a median of 1.5 days for Granollers. All 43 patients were separated from grade Ⅳ neutropenia, of which 13 returned to normal. The main adverse reactions were fever, muscle aches and other performance, are mild and reversible. Conclusions Granolastine is effective in treating chemotherapy-induced neutrophils in lung cancer patients.